Company Alnylam Pharmaceuticals, Inc.

Equities

ALNY

US02043Q1076

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 24/05/2024 BST 5-day change 1st Jan Change
147.8 USD -1.06% Intraday chart for Alnylam Pharmaceuticals, Inc. -1.08% -22.79%

Business Summary

Alnylam Pharmaceuticals, Inc. is a clinical-stage company. The Company is engaged in developing mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead product candidate, Descartes-08, is an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA). Descartes-08 targets BCMA, which exists on the surface of long-lived plasma cells and plasmacytoid dendritic cells. Descartes-08 is in Phase IIb clinical development for patients with generalized myasthenia gravis (MG). Its other product candidate includes Descartes-15 and Descartes-33. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.

Number of employees: 2,100

Sales per Business

USD in Million2022Weight2023Weight Delta
Ribonucleic Acid Interference Therapeutics
100.0 %
1,037 100.0 % 1,828 100.0 % +76.23%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
69.8 %
616 59.4 % 1,276 69.8 % +107.21%
Europe
21.8 %
315 30.4 % 399 21.8 % +26.83%
Rest of the World
8.4 %
107 10.3 % 153 8.4 % +43.31%

Managers

Managers TitleAgeSince
Chief Executive Officer 61 18/09/16
Director of Finance/CFO 56 12/08/19
Compliance Officer - 20/09/22
Chief Tech/Sci/R&D Officer - 31/07/17
Chief Tech/Sci/R&D Officer 56 31/12/04
Chief Tech/Sci/R&D Officer - 30/09/15
Chief Tech/Sci/R&D Officer 56 28/10/14
Public Communications Contact - 31/01/21
Investor Relations Contact 43 31/08/15
Corporate Officer/Principal - -

Members of the board

Members of the board TitleAgeSince
Director/Board Member 70 17/12/15
Director/Board Member 72 21/08/22
Director/Board Member 68 09/01/19
Chairman 63 30/06/14
Founder 79 13/06/02
Director/Board Member 67 06/03/23
Director/Board Member 65 16/12/14
Director/Board Member 78 22/04/12
Director/Board Member 64 31/05/18
Chief Executive Officer 61 18/09/16

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 126,491,778 125,969,953 ( 99.59 %) 0 99.59 %

Shareholders

NameEquities%Valuation
Capital Research & Management Co. (World Investors)
12.97 %
16,398,889 12.97 % 2 357 M $
Capital Research & Management Co. (World Investors)
10.11 %
12,789,236 10.11 % 1 838 M $
Vanguard Fiduciary Trust Co.
9.485 %
11,994,261 9.485 % 1 724 M $
Fidelity Management & Research Co. LLC
7.882 %
9,967,120 7.882 % 1 432 M $
BlackRock Advisors LLC
5.898 %
7,458,197 5.898 % 1 072 M $
Wellington Management Co. LLP
5.736 %
7,252,907 5.736 % 1 042 M $
Wellington Management Co. LLP
5.701 %
7,209,005 5.701 % 1 036 M $
Baillie Gifford & Co.
5.510 %
6,967,097 5.510 % 1 001 M $
Baillie Gifford & Co.
5.238 %
6,623,577 5.238 % 952 M $
Dodge & Cox
3.014 %
3,811,480 3.014 % 548 M $

Company contact information

Alnylam Pharmaceuticals, Inc.

675 West Kendall Street Henri A. Termeer Square

02142, Cambridge

+617 551 8200

http://www.alnylam.com
address Alnylam Pharmaceuticals, Inc.(ALNY)
  1. Stock Market
  2. Equities
  3. ALNY Stock
  4. Company Alnylam Pharmaceuticals, Inc.